The number of COVID-19 indicated medical devices gaining approval in Q1 2022 saw a 34% drop when compared with Q4 2021, according to GlobalData’s medical devices marketed products database

Compared with Q1 2021, the number of COVID-19 indicated medical devices gaining approval in Q1 2022 saw a 61% drop globally.

Europe tops COVID-19 approved medical devices activity

Comparing COVID-19 medical device approvals activity in different regions of the globe, Europe held the top position for approved products (51%) in Q1 2022, followed by Asia-Pacific (28%), and North America (21%).

On a country level, the Germany had the most COVID-19 approved medical devices during the quarter, representing the largest share (38%) of the global market. In second place was India with a share of 11%, followed by Canada with 11%.

COVID-19 marketed medical devices: Development activity in Q1 2022

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData’s database indicated that CE-IVD marketed medical devices that addressed the COVID-19 pandemic accounted for 24% of medical devices in Q1 2022, compared with 24% in Q4 2021.

COVID-19 medical devices obtaining EUA approval declined to 68% in Q1 2022, compared with Q4 2021.

EUA have become more common during the COVID-19 pandemic, as an expeditious mechanism to bring therapeutic devices to market more quickly than normal device approvals.

Company-developed COVID-19 medical devices lead in Q1 2022

GlobalData’s databases indicated that company-developed medical devices accounted for a 100% share of approved COVID-19 devices globally during Q1 2022, while institute-developed marketed products held the remaining share.

The quarterly average for Q1 2022 saw 100% of approved COVID-19 indicated devices originating from private and public companies, and 0% from institutes.

The Covid-19 medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.